Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Depreciation & Amortization (CF) (2017 - 2025)

Arcus Biosciences has reported Depreciation & Amortization (CF) over the past 9 years, most recently at $3.0 million for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $3.0 million for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $10.0 million (changed 0.0% YoY), and the annual figure for FY2025 was $10.0 million, changed 0.0%.
  • Depreciation & Amortization (CF) for Q4 2025 was $3.0 million at Arcus Biosciences, up from $2.0 million in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for RCUS hit a ceiling of $3.0 million in Q4 2023 and a floor of $800000.0 in Q1 2021.
  • Median Depreciation & Amortization (CF) over the past 5 years was $2.0 million (2022), compared with a mean of $1.9 million.
  • Peak annual rise in Depreciation & Amortization (CF) hit 200.0% in 2023, while the deepest fall reached 50.0% in 2023.
  • Arcus Biosciences' Depreciation & Amortization (CF) stood at $1.4 million in 2021, then fell by 29.43% to $1.0 million in 2022, then skyrocketed by 200.0% to $3.0 million in 2023, then changed by 0.0% to $3.0 million in 2024, then changed by 0.0% to $3.0 million in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $3.0 million (Q4 2025), $2.0 million (Q3 2025), and $2.0 million (Q2 2025) per Business Quant data.